Galderma presents 3-year ARCADIA LTE data for Nemluvio in atopic dermatitis
Galderma presented three-year ARCADIA long-term extension study data showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis.
Galderma presented three-year ARCADIA long-term extension study data showing sustained improvements with Nemluvio (nemolizumab) in patients with atopic dermatitis.